AIM Cancer Treatment Pathways: reviewed by oncologists
Pathways are developed using a rigorous process of evidence-based medicine. Cancer Treatment Pathways are selected from therapies recommended by national guidelines on the basis of:
- Clinical benefit (efficacy)
- Side-effects (toxicity), especially those that lead to hospitalizations or impact quality of life
- Strength of national guideline recommendations
- Cost (final consideration when efficacy, toxicity, and national guidelines are equal)
Standards of oncologic care evolve rapidly and keeping pace with change is vital to the health of your patients. That's why it's important to know that the AIM Cancer Treatment Pathways identified in our Program are updated through a systematic review of medical evidence, at least quarterly, and more often when new treatments emerge or national guidelines change. Through the rigor of this process, an up-to-date source of AIM Cancer Treatment Pathways is maintained.
Putting your patients first
We recognize that every patient is unique. While efforts have been made to identify Pathways that offer the best treatment option for most patients, the treating oncologist may decide that another treatment regimen is best for an individual patient.
Whether an AIM Cancer Treatment Pathway or an alternate regimen is chosen, the Medical Oncology Program supports all regimens that meet the clinical review criteria under BCBSNC medical policies and clinical guidelines.